MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
About This Trial
- This study is testing a new computer software program designed to better analyze prostate MRI scans and help doctors locate prostate cancer.
- It is open to adults with known or suspected prostate cancer who are already scheduled for an MRI and a biopsy, and who have not received any prior prostate cancer treatments.
- If you decide to take part, your participation will last about one year and will involve a single MRI scan, one or two biopsies, and regular check-ins so doctors can monitor your health progress.
More Information
- Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate.
- Participation in this research will last about 12 months.
- There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.
Who Can Enroll
- Age Range: 18 years and older
- Gender: Male
- Who This Trial is For: This study is testing a new computer software program designed to better analyze prostate MRI scans and help doctors locate prostate cancer.
Study Details
- Start Date: April 26, 2023
- Lead Sponsor: University of Chicago
Full Eligibility Criteria
Inclusion Criteria
- Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
- Voluntary written informed consent before the MRI examination.
Exclusion Criteria
- Subjects incapable of giving informed written consent.
- Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
- Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
- Prisoners.
- Minor children (under the age of 18 years old).
- Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.
Treatments
- Other: Risk Map Decision Support System (DSS).
- Radiation: Magnetic Resonance Imaging (MRI)
- Procedure: Magnetic Resonance Imaging (MRI) Guided Biopsy